FOLFOX3 in heavily pretreated patients with metastatic colorectal cancer.
作者： C. J. Van Groeningen , E. Boven , N. Croles , C. H. Smorenburg , G. Giaccone
DOI:
关键词: Vomiting 、 Progressive disease 、 Regimen 、 Nausea 、 Colorectal cancer 、 Gastroenterology 、 Toxicity 、 Chemotherapy 、 Internal medicine 、 Oxaliplatin 、 Medicine
摘要: Background: The combination of oxaliplatin, 5-fluorouracil (5FU) and leucovorin (LV) has shown to be active safe as first- or second-line chemotherapy for metastatic colorectal cancer (MCC). Patients Methods: outcome patients with MCC who had progressive disease after at least two lines palliative were subsequently treated 5FU LV was reviewed. received FOLFOX3 consisting oxaliplatin (85 mg/m 2 ) on day 1, (500 a two-hour infusion days 1 2, (3000 46-hour starting in cycle weeks. Results: A total 28 median number 9.5 cycles (range 1-24) mean dose intensity 73%. Six discontinued treatment due toxicity, whom three sensory neuropathy grade 2. experienced 3 toxicity: nausea (1), vomiting diarrhoea leucopenia (2) thrombocytopenia (1); 4 toxicity not observed. Twenty-five evaluable response, four achieved partial response (response rate 14%, based intention treat). progression-free survival 5.8 months the overall 8.5 months. Conclusion: For heavily pretreated MCC, regimen is fairly effective treatment.
参考文章(12)
Thierry André, Mohamed A. Bensmaine, Christophe Louvet, Eric François, Virginie Lucas, Françoise Desseigne, Karine Beerblock, Olivier Bouché, Elisabeth Carola, Yacine Merrouche, François Morvan, Ghislaine Dupont-André, Aimery de Gramont, Multicenter Phase II Study of Bimonthly High-Dose Leucovorin, Fluorouracil Infusion, and Oxaliplatin for Metastatic Colorectal Cancer Resistant to the Same Leucovorin and Fluorouracil Regimen Journal of Clinical Oncology. ,vol. 17, pp. 3560- 3568 ,(1999) , 10.1200/JCO.1999.17.11.3560
Alfredo Carrato, Javier Gallego, Eduardo Dı́az-Rubio, Oxaliplatin: results in colorectal carcinoma Critical Reviews in Oncology Hematology. ,vol. 44, pp. 29- 44 ,(2002) , 10.1016/S1040-8428(01)00192-5
A. de Gramont, J. Vignoud, C. Tournigand, C. Louvet, T. André, C. Varette, E. Raymond, S. Moreau, N. Le Bail, M. Krulik, Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer European Journal of Cancer. ,vol. 33, pp. 214- 219 ,(1997) , 10.1016/S0959-8049(96)00370-X
Hedy Lee Kindler, Keith L. Shulman, Metastatic colorectal cancer Current Treatment Options in Oncology. ,vol. 2, pp. 459- 471 ,(2001) , 10.1007/S11864-001-0068-7
T. André, C. Louvet, E. Raymond, C. Tournigand, A. de Gramont, Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen Annals of Oncology. ,vol. 9, pp. 1251- 1253 ,(1998) , 10.1023/A:1008475122124
F Maindrault-Gæbel, A De Gramont, C Louvet, T Andre, E Carola, V Gilles, J-P Lotz, C Tournigand, M Mabro, J-L Molitor, P Artru, V Izrael, M Krulik, Oncology Multidisciplinary Research Group, None, Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer Annals of Oncology. ,vol. 11, pp. 1477- 1483 ,(2000) , 10.1023/A:1026520812351
Mace L. Rothenberg, Amit M. Oza, Robert H. Bigelow, Jordan D. Berlin, John L. Marshall, Ramesh K. Ramanathan, Lowell L. Hart, Sunil Gupta, Carlos A. Garay, Brent G. Burger, Nathalie Le Bail, Daniel G. Haller, Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial Journal of Clinical Oncology. ,vol. 21, pp. 2059- 2069 ,(2003) , 10.1200/JCO.2003.11.126
Werner Scheithauer, Gabriela V. Kornek, Markus Raderer, Birgit Schüll, Katharina Schmid, Erwin Kovats, Bruno Schneeweiss, Fritz Lang, Alfred Lenauer, Dieter Depisch, Randomized Multicenter Phase II Trial of Two Different Schedules of Capecitabine Plus Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer Journal of Clinical Oncology. ,vol. 21, pp. 1307- 1312 ,(2003) , 10.1200/JCO.2003.09.016
Richard M. Goldberg, Daniel J. Sargent, Roscoe F. Morton, Charles S. Fuchs, Ramesh K. Ramanathan, Stephen K. Williamson, Brian P. Findlay, Henry C. Pitot, Steven R. Alberts, A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 22, pp. 23- 30 ,(2004) , 10.1200/JCO.2004.09.046
Markus M. Borner, Daniel Dietrich, Roger Stupp, Rudolf Morant, Hanspeter Honegger, Martin Wernli, Richard Herrmann, Bernhard C. Pestalozzi, Piercarlo Saletti, Silvia Hanselmann, Samuel Müller, Peter Brauchli, Monica Castiglione-Gertsch, Aron Goldhirsch, Arnaud D. Roth, Phase II study of capecitabine and oxaliplatin in first-and second-line treatment of advanced or metastatic colorectal cancer Journal of Clinical Oncology. ,vol. 20, pp. 1759- 1766 ,(2002) , 10.1200/JCO.2002.07.087